You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
PREFAB MODULAR LIQUID-COOLED MICRO DATA CENTER
SBC: Flexnode Inc Topic: 1"To enable the future needs of efficient computing for edge data centers, Flexnode and its partners, the University of Maryland (UMD), Boeing, Iceotope, SHoP Architects, and Arup, propose to develop a prefabricated modular micro data center with unprecedented energy efficiency and power density. The proposed system leverages four key component and system-level technology advancements: (a) a novel, ...
STTR Phase I 2024 Department of EnergyARPA-E -
Low Cost All Temperature Zinc-pulp Battery for Stationary Storage
SBC: WH-POWER INC Topic: CWH-Power (WattHour-Power, or WHP) and University of Maryland (Profs. Chunsheng Wang and Laingbing Hu) propose to produce a high entropy electrolyte (HEE) and pulp based low-cost zinc battery with –80 ˚C to 80 ˚C operation temperature range for stationary storage (grid and residential energy storage). The zinc-pulp battery is inherently safe, the cost to produce and use the battery is low, and ...
SBIR Phase I 2023 Department of EnergyARPA-E -
Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.
SBC: PREVEP, LLC Topic: NINDSAbstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Staph Aureus Vaccine
SBC: BIOLOGICAL MIMETICS, INC. Topic: NIAIDAbstract Methicillin-resistant Staphylococcus aureus is often considered the prototype hospital-acquired infection. In spite of the billions of dollars spent on preventive measures, estimates of the incidence are in the hundreds of thousands, with tens of thousands of people per year succumbing to disease in the USA alone. Prophylactic vaccines against S. aureus would have an enormous impact in th ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro
SBC: SANARIA INC. Topic: NIAIDIn 2022 WHO called for highly efficacious vaccines against malaria that prevent Plasmodium falciparum (Pf) infection in rt 90% of recipients. Alone among malaria vaccines, Sanaria® PfSPZ (Pf sporozoite (SPZ)) vaccines have shown rt 90% vaccine efficacy (VE) against controlled human malaria infection and VE against intense field transmission of malaria to pregnant women for two transmission years ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inducible HMGB1 antagonist for viral-induced acute lung injury.
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NHLBIFor more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Improving Analgesic Effectiveness and Safety with Proactive Precision Pain Management in Thoracic Surgical Patients with Lung Lesions
SBC: OpalGenix, Inc. Topic: NHLBIPROJECT SUMMARY Thoracic surgery (TS), especially pneumonectomy, lobectomy and segmentectomy, are common and very painful surgeries for lung lesions with high incidence of uncontrolled acute surgical pain, chronic post- thoracotomy pain and excessive opioid use. Those with poorly controlled acute surgical pain are at risk for chronic post-surgical pain (CPSP), long-term opioid use and opioid addic ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of optimized adeno-associated viral capsids for muscle gene therapy
SBC: AAVOGEN INC Topic: NIAMSPROJECT SUMMARY. Gene therapeutics offer hope to many patients with rare muscle and neuromuscular diseases. Despite some early successes, several serious off-target safety concerns have compromised their development due to hepatic toxicities and related immune responses to the adeno-associated viral (AAV) vectors. The generation of novel capsids with superior muscle specificity could, therefore, r ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
SBC: CREATIVE BIO-PEPTIDES INC Topic: NIA7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.
SBC: Zylo Therapeutics Inc. Topic: NIAMSProject Summary/Abstract Approximately 500,000 people in the U.S. suffer from cutaneous lupus lesions (CLE), with a significant impact on quality of life.4 Yet, there is no cure, the treatment options are limited, and no new drug has been FDA- approved for over 50 years.84 As such, CLE represents a high unmet need for directed therapeutics. Skin lesions are caused by a complex autoimmune response ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health